An exploratory integrative analysis of plasma transcriptomic and proteomic predictors of response to total neoadjuvant therapy in locally advanced rectal cancer - Summary - MDSpire
Advertisement
An exploratory integrative analysis of plasma transcriptomic and proteomic predictors of response to total neoadjuvant therapy in locally advanced rectal cancer
To screen and identify plasma biomarkers associated with treatment response to total neoadjuvant therapy (TNT) in patients with locally advanced rectal cancer (LARC) to predict pathological complete response (pCR).
Key Findings:
365 DEGs were upregulated and 198 were downregulated in the pCR group compared to the non-pCR group.
The identified DEGs are involved in pathways related to cell growth and death, signal transduction, metabolism, the immune system, insulin secretion, mitophagy, and neutrophil extracellular trap formation.
Plasma levels of Fas ligand (FASLG), CD160, and LYPD3 were higher in the pCR group than in the non-pCR group.
A multi-marker panel consisting of FASLG, CD160, and LYPD3 showed an AUC of 0.791 in predicting pCR.
Interpretation:
Remove this section.
Limitations:
The transcriptomic analysis was conducted in a limited discovery cohort.
The identified DEGs should be interpreted with caution due to the high risk of false discovery.
